Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Catonsville, Maryland Clinical Trials

A listing of Catonsville, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (327) clinical trials

Study To Evaluate the Efficacy Safety and Tolerability of E2027 in Participants With Dementia With Lewy Bodies

This study will be conducted to compare E2027 to placebo on the cognitive endpoint of Montreal Cognitive Assessment (MoCA) and the global clinical endpoint of Clinician's Interview Based Impression of Change Plus (CIBIC-Plus) Caregiver Input in participants with dementia with Lewy bodies after 12 weeks of treatment.

Phase

0.0 miles

Learn More »

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

Phase

0.0 miles

Learn More »

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Allogeneic hematopoietic stem cell transplantation (aHSCT) can cure patients with a variety of bone marrow failure syndromes (BMFS) including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias. Patients with BMFS have traditionally been transplanted with bone marrow (BM) as a stem cell source. ...

Phase

0.0 miles

Learn More »

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

The purpose of the study is to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Phase

0.0 miles

Learn More »

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

The trial will enroll up to 20 participants. Following enrollment, participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose of olaparib will be increased to 300mg by mouth twice daily provided there are no grade 3 or ...

Phase

0.0 miles

Learn More »

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

This is a single-center, single arm, open-label phase II study evaluating the safety, anti-tumor effect, and immunogenicity of neoadjuvant Dupixent given prior to radical prostatectomy in men with high-risk localized prostate cancer (this trial will enroll men with at least high risk prostate cancer defined by NCCN Guidelines Version 2.2017 ...

Phase

0.0 miles

Learn More »

Primary Outcome Measures  :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis [ Time Frame: Up to approximately 52 weeks ]Assessment of liver fibrosis score by the NASH Clinical Research Network (CRN) scoring systemSecondary Outcome Measures  :Proportion of subjects who achieve a ≥1 stage improvement in liver fibrosis and no worsening of steatohepatitis ...

Phase

0.0 miles

Learn More »

The purpose of this Study is to find out if the study drug ruxolitinib (“Study Drug” or ruxolitinib) is safe and effective compared to anagrelide hydrochloride (also known as Agrylin® or anagrelide), in people who have Essential Thrombocythemia (ET) and are resistant to or intolerant of Hydroxyurea. 

Phase

2.52 miles

Learn More »

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

PRIMARY OBJECTIVES: I. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients treated with durvalumab (MEDI4736) plus tremelimumab. SECONDARY OBJECTIVES: I. To estimate the duration of response (DoR) among patients who achieve a complete response (CR) ...

Phase

2.73 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

2.73 miles

Learn More »